Pertussis vaccines: present status.

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Pertussis (whooping cough) continues to cause significant mortality and morbidity globally, particularly in regions with limited mass immunization programs.
• Whole-cell pertussis vaccines (WCPV) are effective but associated with infant reactogenicity, driving research into alternative formulations.
• Achieving high immunization coverage is crucial for pertussis control.

Purpose of the Study:

• To review the progress in developing and implementing acellular pertussis vaccines (aP).
• To assess the safety and efficacy of aP compared to WCPV.
• To discuss the future prospects of pertussis vaccine development for disease eradication.

Main Methods:

• Review of recent advancements in acellular pertussis vaccine technology.
• Analysis of clinical trial data and real-world usage of acellular pertussis vaccines.
• Discussion of factors influencing vaccine production and public acceptance.

Main Results:

• Acellular pertussis vaccines have been developed and are in routine use, demonstrating improved safety profiles for infants compared to WCPV.
• Clinical studies in Japan, Sweden, and other countries indicate that acellular vaccines are as effective as conventional whole-cell vaccines in preventing pertussis.
• Gene manipulation holds promise for future vaccine development, potentially enhancing public confidence.

Conclusions:

• Acellular pertussis vaccines represent a significant advancement, offering enhanced safety and comparable efficacy to whole-cell vaccines.
• While acellular vaccines improve disease control, widespread use of conventional whole-cell pertussis vaccines may persist in some regions due to production and accessibility factors.
• Future development of sophisticated acellular pertussis vaccines could pave the way for global pertussis eradication.